Upstaza (eladocagene exuparvovec)
Aromatic L-amino acid decarboxylase (AADC) deficiency
ApprovedCommercial
Key Facts
Indication
Aromatic L-amino acid decarboxylase (AADC) deficiency
Phase
Approved
Status
Commercial
Company
About PTC Therapeutics
PTC Therapeutics is a patient-centric, publicly traded biopharma leader dedicated to translating groundbreaking science into life-changing treatments for rare diseases. Its key achievements include commercializing a series of 'firsts' in rare disease treatment and building a diversified pipeline targeting neurological and metabolic disorders. The company's strategic direction is fueled by its deep expertise in two core scientific platforms—splicing modifiers and inflammation/ferroptosis inhibitors—and a robust global commercial infrastructure to support its mission of delivering transformative medicines worldwide.
View full company profile